Kidney Pancreas Transplant Clinical Trial
Official title:
Assessment of Donor Derived Cell-free DNA in Combined Kidney-pancreas Recipients
This study will observe donor derived cell free DNA percentages (via the Allosure test) in combined kidney-pancreas transplant recipients to establish both stable and dysfunctional Allosure assay levels
Simultaneous kidney-pancreas transplantation is the optimal treatment for select patients with type 1 diabetes and kidney failure. Limited biomarkers are utilized to monitor the health of the allografts. For kidney transplantation serum creatinine remains the most commonly monitored biomarker; for the pancreas allograft blood glucose and serum amylase and lipase are measured. However, these biomarkers are imprecise and non-specific for rejection. In kidney transplantation cell free donor derived DNA at of value of >1% has emerged as an effective immune monitoring tool as a marker for renal allograft rejection and injury. Thus far, a discriminatory donor derived cell free DNA value for a stable and rejecting allografts has not been established for recipients of combined kidney-pancreas transplants. Study aim will be to help establish a normal range of donor derived cell free DNA in stable kidney-pancreas graft function in combined kidney pancreas transplant recipients while determining changes in cell free DNA in kidney-pancreas recipients with biopsy proven allograft rejection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01860820 -
The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema
|
N/A | |
| Completed |
NCT01410162 -
Advagraf/Prograf Conversion Trial
|
Phase 4 |